New hope for kids with Tough-to-Treat lymphoma
NCT ID NCT07168980
Summary
This study is testing if using a stronger chemotherapy schedule and giving more doses of a targeted drug called rituximab can improve survival for children and adolescents with aggressive B-cell lymphoma. It aims to help patients with high-risk disease who had lower survival rates in past studies. The trial is comparing this new, more intensive approach to results from a previous treatment plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Children's Medical Center
RECRUITINGShanghai, Shanghai Municipality, 201315, China
Conditions
Explore the condition pages connected to this study.